Results 31 to 40 of about 3,116,614 (307)

Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis [PDF]

Journal of Experimental & Clinical Cancer Research, 2020
Background The identification of novel targets for recovering sorafenib resistance is pivotal for Hepatocellular carcinoma (HCC) patients. Mitophagy is the programmed degradation of mitochondria, and is likely involved in drug resistance of cancer cells.
Hong Wu, Tao Wang, Yiqiang Liu, Xin Li, Senlin Xu, Changtao Wu, Hongbo Zou, Mianfu Cao, Guoxiang Jin, Jinyi Lang, Bin Wang, Baohua Liu, Xiaolin Luo, Chuan Xu   +13 more
doaj   +3 more sources

CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p/SLC7A11 axis. [PDF]

Mol Cancer
The high mortality rate from hepatocellular carcinoma (HCC) is due primarily to challenges in early diagnosis and the development of drug resistance in advanced stages.
Zhang Y, Yao R, Li M, Fang C, Feng K, Chen X, Wang J, Luo R, Shi H, Chen X, Zhao X, Huang H, Liu S, Yin B, Zhong C.   +14 more
europepmc   +2 more sources

Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma [PDF]

Journal of Experimental & Clinical Cancer Research, 2019
Background Sorafenib is the first-line treatment for advanced-stage hepatocellular carcinoma (HCC). Several studies have shown that the up-regulation of β-catenin plays a role in sorafenib resistance in HCC; however, the mechanism associated with this ...
Ling Deng, Jingyuan Sun, Xiaohui Chen, Li Liu, Dehua Wu   +4 more
doaj   +2 more sources

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway [PDF]

Cell Death and Disease
Sorafenib is an antiangiogenic and antiproliferative chemotherapeutic drug that plays a crucial role in the treatment of patients with advanced hepatocellular carcinoma (HCC). However, resistance to sorafenib greatly limits its therapeutic efficacy. This
Ruimei Ren, Shan Zhang, Zhan Peng, Xiaomeng Ji, Hao Song, Qiuxiao Wang, Xiangyin Sun, Huiyu Wang, Yinying Dong   +8 more
doaj   +2 more sources

IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis

Frontiers in Immunology
IntroductionSorafenib is currently the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Nevertheless, sorafenib resistance remains a huge challenge in the clinic.
Junzhang Chen, Shiran Sun, Hui Li, Xiong Cai, Chidan Wan   +4 more
doaj   +2 more sources

Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy

Stem Cell Research & Therapy, 2023
Background Sorafenib is a first-line drug targeting the RTK-MAPK signalling pathway used to treat advanced hepatocellular carcinoma (HCC). However, tumour cells readily develop sorafenib resistance, limiting long-term therapy with this drug.
Sining Zhou, Yiming Liu, Qi Zhang, Huikang Xu, Yangxin Fang, Xin Chen, Jiamin Fu, Yin Yuan, Yifei Li, Li Yuan, Charlie Xiang   +10 more
doaj   +2 more sources

The Role of Bcl-2 Family Proteins and Sorafenib Resistance in Hepatocellular Carcinoma. [PDF]

Int J Cell Biol
Liver cancer has been reported to be one of the most malignant diseases in the world. It is late diagnosis consequently leads to a difficult treatment, as the cancer reached an advanced stage.
de Melo Silva AJ, de Melo Gama JE, de Oliveira SA.   +2 more
europepmc   +2 more sources

The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma

Frontiers in Oncology, 2023
Hepatocellular carcinoma (HCC) is a heterogeneous and aggressive liver cancer that presents limited treatment options. Despite being the standard therapy for advanced HCC, sorafenib frequently encounters resistance, emphasizing the need to uncover the ...
Siqi Chen, Siqi Chen, Siqi Chen, Yaqing Du, Xin-Yuan Guan, Qian Yan, Qian Yan, Qian Yan   +7 more
doaj   +2 more sources

NAT10 inhibition promotes ac4C-dependent ferroptosis to counteract sorafenib resistance in nasopharyngeal carcinoma. [PDF]

Cancer Sci
Sorafenib, an anticancer drug, has been shown to induce ferroptosis in cancer cells. However, resistance to sorafenib greatly limits its therapeutic efficacy, and the exact mechanism of resistance is not fully understood. This study investigated the role
Xue Z, Xie H, Shan Y, Zhang L, Cheng L, Chen W, Zhu R, Zhang K, Ni H, Zhang Z, You Y, You B.   +11 more
europepmc   +2 more sources

GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. [PDF]

Theranostics
Background: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC), but acquired resistance during the treatment greatly limits its clinical efficiency.
Zhou Y, Zhao H, Ren R, Zhou M, Zhang J, Wu Z, Chen Y, Lei J, Chen Y, Yu Y, Li Y.   +10 more
europepmc   +2 more sources